Randomized clinical trials are often considered the highest level on which medical care should be based.
As the rate of acceleration in ESRD incidence decline, physicians should expect heightened battles for the ESRD fountains.
Patients diagnosed with prostate cancer often struggle with their diagnosis.
Renal & Urology News interviewed Matthew R. Weir, MD, director of the division of nephrology and professor of medicine at the University of Maryland School of Medicine in Baltimore.
If ESRD patients face increasing difficulty getting a kidney transplant in coming years, they may see an artificial kidney as the next best alternative.
Additional novel medical therapies to treat prostate cancer and earlier use of the existing medical therapies are the future of prostate cancer management.
Advances in prostate cancer screening, management and therapeutics have vastly improved patient care.
No matter how much pharmacologic therapy advances, patient behavior will remain a significant factor in the outcomes achieved.
We may feel good treating a patient's edema, but is fluid retention always harmful?
Chronic diseases such as end-stage renal disease (ESRD) have now surpassed opportunistic infections as the leading cause of death among HIV-infected patients.
Daniel Canter, M.D., discusses narrow-band imaging (NBI) for visualization of bladder cancer.
For decades, prostate cancer risk (PCa) stratification was based primarily on the architectural pattern of the tumor.
Among the most important challenges in producing a medical newspaper is deciding what studies or topics on which to report.
Recently, increasing attention focused on mineralocorticoid receptor antagonists (MRAs) in treating chronic kidney disease (CKD).
Dr. Kalantar-Zadeh: Patients with Ebola deserve to be offered renal replacement therapy, even if odds of survival are slim.
Eisenhower warned Americans to beware of the "military-industrial complex" as it can overwhelm us.
The separation of continents no longer provides a secure buffer against the spread of communicable diseases from far-flung places.
Would any heterogeneity in the choice of additional services be unethical or implausible?
We crave clinical and scientific data, yet we grieve the performance-based data increasingly directed toward us.
Dr. Moe spoke about the importance of nephrology research and how a prize competition can facilitate the process.
Many patients still insist that I need to check and manage their cholesterol.
Jonathan Harper, MD, of the UW School of Medicine in Seattle, explains his "Rolling Stones" concept as a feasible office procedure.
For the first time, the federal CMS has made public a database showing what it pays out to individual physicians.
We sat down with Dr. Eid at his New York City office to ask him about the latest developments in penile implant therapy.
CORAL study chair Lance Dworkin, MD, discusses the controversial finding with Renal & Urology News.
Human beings are unique in the animal kingdom when it comes to nutrition.
Rising readmission rates of subsequent sepsis have given urologic surgeon Jeremy Grummet, MBBS, MS, FRACS, pause.
The term "personalized medicine" remains an overused promise to apply specific treatment plans.
Immunologic mismatch may no longer be a barrier between living kidney donors and recipients.
This higher level of dialysis care in Canada is partly owed to substantially higher reimbursement fees for nephrologists.
Some may find it surprising that Dr. Critz generally considers RP to be the go-to treatment for localized disease.
When we move from one state to another, typically we must obtain a driver's license from the state to which we are relocating.
A digital sensing platform could allow patients with chronic kidney ailments or diabetes to test their own urine albumin levels.
As a venue for presenting important research on kidney disease to the world, Kidney Week never disappoints.
Urologist Ronald K. Loo, MD, of Southern California Permanente Medical Group and colleagues created and validated a Hematuria Risk Index.
After the end of 16-day federal shutdown in October, media headlines touted the financial impact on America and the cost of restarting the government.
Hyponatremia authority Dr. Juan Carlos Ayus receives calls all the time from fellow nephrologists who have questions.
Over the past 10 years the annual ESRD incidence rate per million U.S. population has remained stagnant or even shown sporadic downward trends.
Radium-223 was approved in May 2013 for the treatment of mCRPC with symptomatic bone metastases and no visceral disease.
For men at risk of developing prostate cancer (PCa), prophylactic prostatectomy seems almost irrational for several reasons
A nascent technology combines laser optics and ultrasound to distinguish between benign and malignant prostate tissue.
Once again, a study offers evidence that one of the keys to good nutrition is avoiding excess.
Dr. Crispen highlights the advantages and challenges of active surveillance for small renal masses.
In the nephrology community, there have been heightened discussions and apparent enthusiasm about the revival of PD as the prototype for home dialysis.
David O. Sussman, DO, has been ready to educate urology colleagues on the appropriate use of Botox.
The vow never to treat SRMs may seem hard to believe and self-defeating.
The MENTOR study is poised to change first-line-treatment recommendations for idiopathic membranous nephropathy.
Two studies presented at the recent NKF Spring Clinical Meetings provide more evidence of a trend toward decreasing use of ESAs and decreasing hemoglobin levels.
Provenge is a breatkthrough treatment option for men with asymptomatic or minimally symptomatic metastatic, hormone-resistant PCa.
Having just returned from the always-stimulating European Association of Urology annual congress, I'd like to share a few impressions.
The scar tissue that forms on sections of some glomeruli in FSGS will lead to kidney failure if left untreated.
Almost half a million Americans depend on chronic dialysis therapy to survive.
Ringing in the new year was especially exciting this time around for Ashutosh K. Tewari, MB, BS, head of the new Center for Prostate Cancer at New York-Presbyterian.
Physicians are more often defined by their ability to diagnose, treat, and research a disease than their willingness to manage its spectrum of risk.
The incidence of AKI requiring dialysis is now higher than the incidence of ESRD requiring dialysis or transplant.
How often have you met for business in a Starbucks, Coffee Bean, or any other coffee shop?
A promising hybrid device that works from the inside to provide renal functions beyond dialysis 24 hours a day, seven days a week, has the potential to change a lot of lives.
Kidney Week 2012, held in San Diego, is now history and as usual I like to reflect on the world's biggest and most prestigious meeting for kidney specialists.
Considering that bone loss is a known side effect of ADT for men with PCa, it might seem logical that calcium and vitamin D supplementation would help manage this consequence.
Although data suggest that cancer rates are also higher in obese patients, the associations are largely based on observational/population studies.
Focusing on nephrology patients who become pregnant may seem to be a niche business, but as specialist Madeleine Pahl, MD, tells Renal & Urology News, this population is increasing.
President Obama and Mitt Romney square off on American health reform in the New England Journal of Medicine.
Historically, foamy urine is considered a warning sign for probable kidney disease.
Robert K. Nam, MD, MSc, and colleagues helped to shed light on the impact of UI in men who have undergone RP by studying rates of UI-corrective surgery.
Cross-sectional imaging now substitutes for physical diagnosis in most emergency rooms.
Nephrologist and study coauthor Yoshio Hall, MD, discusses his team's findings with Renal & Urology News.
In recent trips to India, China, Brazil, and other countries, I was intrigued by large numbers of patients with end-stage renal disease who underwent hemodialysis (HD) less frequently than three times a week.
Dr. Clayman continues to make his mark as one of only two urologists in the nation to become a medical school dean.
In the past few years, urologists have seen some significant developments related to the treatment of metastatic castration-resistant prostate cancer (CRPC).
Nobody had to ask Oliver Khakmahd, MD, twice to implement an EHR system in his large, busy nephrology practice.
Unfortunately, in the past few years, very few studies have looked at issues regarding gender and CKD, and of most concern, looking at response to therapy.
Several new drugs have become available for treating advanced prostate cancer in the past year and a half.
More than 1 million prostate biopsies are performed annually in the United States, predominantly driven by elevations in PSA.
When using ESAs to correct anemia in patients with chronic kidney disease, focus less on hitting a given hemoglobin target.
As practicing clinicians in the United States, we generally feel privileged, with access to a highly developed and pioneering medical care system along with an advanced and cutting-edge technology in the world's largest economy.
Having performed more than 1,200 brachytherapy treatments, Michael F. Sarosdy, MD, is convinced that this is a far better choice than surgery.
The March issue features coverage of the 2012 Genitourinary (GU) Cancers Symposium, which was held in San Francisco.
An impressive story of a dialysis survivor who watched his daughters grow and getting married, and had the joy of knowing several grandchildren.
FGF-23 may one day be an important marker of and therapeutic target for very early-stage CKD for the clinical nephrologist.
How often do you face with the unpleasant task of waking a sleeping patient during your busy rounds? It happens frequently to many clinicians during their inpatient rounds in the hospital.
Although HIFU has not yet been approved in the US, a growing number of the nation's urologists are offering this noninvasive surgical procedure.
The start of 2012 is a good time to look back on the previous year to see the current state of nephrology. What have been the important findings that occurred in the past year, and what do we have to look forward to in the year ahead?
Less than a decade ago, Aaron Tobian, MD, PhD, would not have been a proponent of male circumcision.
For the ninth straight year, I came away from Kidney Week (formerly Renal Week), the annual scientific meeting of the American Society of Nephrology, feeling badly that Renal & Urology News can only report on a fraction of the thousands of studies presented at the meeting.
According to current estimates, kidney stones will develop in one in 10 people during their lifetime. This translates into nearly 30 million people in the United States. Clearly, prevention is paramount when dealing with kidney stones.
Individuals, businesses and nations grapple with how to measure success. Are similar productivity measures warranted in medicine?
A leading authority on kidney stone disease, James E. Lingeman, MD, updates Renal & Urology News on the state of urinary stone treatment.
Dr. Hellstrom, is one of the principal investigators involved in studies of avanafil, an investigational phosphodiesterase-5 inhibitor.
There has recently been a tremendous increase in emphasis on quality and patient safety within American medicine. Much of this is due to an improved ability to look at and evaluate results from large numbers of patients and determine "best practices" shown to improve outcomes.
The renal function preservation clinic for patients with kidney cancer represents a new multidisciplinary approach to an old problem.
Physicians are indeed spending less face time with patients, according to studies and to what doctors have told me in conversation. One consequence of this could be less time to educate patients about their illness.
Many obese dialysis patients are asked to lose weight to qualify for kidney transplantation. If such usual weight reduction programs as dieting or anti-appetite medications do not work, some patients will be introduced to more aggressive interventions such as bariatric surgery.
HIV is no longer a contraindication to transplantation, contends Dorry Segev, MD, PhD.
George Bakris, MD, spoke about various aspects of treating hypertension in patients with chronic kidney disease.
Traditional nephrology training makes us believe that it is good practice to start maintenance dialysis therapy sooner rather than later. Nevertheless, recent data indicate that we may encounter yet another "old-practice-was-wrong" paradigm shift.
Mani Menon, MD, discusses the place of robotic prostatectomy in the treatment of localized prostate cancer.
Incidentally detected renal tumors are increasingly diagnosed in patients with chronic kidney disease.
Renal and Urology News Articles
- FDA Recalls Drugs Containing Active Ingredient Valsartan
- Correcting Metabolic Acidosis May Preserve Muscle Mass
- Infection Risk Lower in Dialysis Patients With High, Normal Vitamin D
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Aggressive Therapy Warranted for Gleason 10 Prostate Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)